Axiom Investors LLC DE Sells 2,599 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Axiom Investors LLC DE trimmed its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 4.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 60,101 shares of the biopharmaceutical company’s stock after selling 2,599 shares during the period. Axiom Investors LLC DE’s holdings in Intra-Cellular Therapies were worth $5,020,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Wellington Management Group LLP boosted its stake in shares of Intra-Cellular Therapies by 1.6% in the 4th quarter. Wellington Management Group LLP now owns 1,033,743 shares of the biopharmaceutical company’s stock valued at $86,338,000 after purchasing an additional 16,096 shares during the last quarter. Norges Bank bought a new position in Intra-Cellular Therapies in the fourth quarter valued at approximately $268,347,000. EFG Asset Management North America Corp. grew its holdings in Intra-Cellular Therapies by 99.8% during the 4th quarter. EFG Asset Management North America Corp. now owns 74,190 shares of the biopharmaceutical company’s stock worth $6,200,000 after acquiring an additional 37,061 shares during the period. Vanguard Group Inc. raised its position in shares of Intra-Cellular Therapies by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 9,721,360 shares of the biopharmaceutical company’s stock valued at $811,928,000 after acquiring an additional 93,107 shares during the last quarter. Finally, LPL Financial LLC lifted its stake in shares of Intra-Cellular Therapies by 38.7% in the 4th quarter. LPL Financial LLC now owns 28,258 shares of the biopharmaceutical company’s stock valued at $2,360,000 after purchasing an additional 7,878 shares during the period. 92.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on ITCI shares. Piper Sandler reaffirmed a “neutral” rating and set a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and lifted their price objective for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. Baird R W cut shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, StockNews.com started coverage on shares of Intra-Cellular Therapies in a report on Friday. They issued a “hold” rating on the stock. Ten investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $106.08.

Intra-Cellular Therapies Stock Up 0.1 %

NASDAQ ITCI opened at $131.92 on Tuesday. Intra-Cellular Therapies, Inc. has a 12-month low of $64.09 and a 12-month high of $131.95. The firm’s 50 day moving average is $129.23 and its 200-day moving average is $100.20. The company has a market capitalization of $14.05 billion, a PE ratio of -151.63 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The business had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. As a group, sell-side analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.